Reports Produced by Inpart 19 May 2025Oncology R&D trends and breakthrough innovations Explore the latest in oncology R&D with Inpart’s new trends report, featuring emerging technologies, breakthrough innovations, and expert insights shaping the future of cancer research. May 19, 2025 Share WhatsApp Twitter Linkedin Email Produced by Inpart
News and Trends 24 Mar 2025 First-ever RIPTAC enters clinic: all you need to know about this new cancer approach The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics. March 24, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Sep 2023 Recent advancements in prostate cancer research over the past year Prostate cancer is the second most commonly occurring cancer in men. More than 1.4 million people were diagnosed with prostate cancer in 2020, according to the World Cancer Research Fund International. While some prostate cancers develop too slowly, to the extent that some people will not need any treatment during their lifetime, some grow very […] September 21, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Promising results from phase 3 prostate cancer study Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS) in men with non-metastatic hormone-sensitive prostate […] May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […] May 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 New radiopharmaceutical shrinks prostate cancer tumors Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively shrinks prostate tumors in mice. The team reported the anti-cancer treatment zeroes in on tumor cells with ‘laser precision.’ Recent developments, such as targeted α-therapies as a type of theranostics, are trying to tackle cancer. Theranostics is a one-two punch […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 New study shows how prostate cancer may start Researchers at the University of East Anglia in the U.K. say they have made an important discovery about how prostate cancer may start to develop. A new study published in Molecular Oncology reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email